Author: Shaheen Philip E Bukowski Ronald M
Publisher: Informa Healthcare
ISSN: 1472-8214
Source: Expert Opinion on Emerging Drugs, Vol.10, Iss.4, 2005-11, pp. : 773-795
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Renal cell carcinoma (RCC) still represents a therapeutic challenge when patients have advanced or metastatic disease. Treatment using IL-2 and IFN-α continues to be the standard of care in patients who are able to tolerate such regimens. Targeted therapy may become the first-line treatment for patients resistant or intolerant to cytokines as new emerging drugs continue to be investigated. Understanding the genetic abnormalities related to the development of RCC (e.g., VHL gene abnormalities) and identifying molecular targets (e.g., epidermal growth factor, vascular endothelial growth factor and carbonic anhydrase IX) are playing a major role in the emergence of these novel agents for the treatment of this malignancy. Overall, these drugs are better tolerated and more acceptable to use by patients than the traditional cytokine-based regimens. The use of oral drugs to treat various malignancies including RCC seems to be the new paradigm of the future. Further understanding of their mechanisms of action and confirmation of their benefits on the clinical outcome is needed.
Related content
Emerging drugs for renal cell carcinoma
By Varella Leticia Rini Brian I
Expert Opinion on Emerging Drugs, Vol. 15, Iss. 3, 2010-09 ,pp. :
Novel drugs for renal cell carcinoma
By Vakkalanka Bhanu K Bukowski Ronald M
Expert Opinion on Investigational Drugs, Vol. 17, Iss. 10, 2008-10 ,pp. :
Emerging Targeted Therapies in Metastatic Renal Cell Carcinoma
Current Clinical Pharmacology, Vol. 6, Iss. 3, 2011-08 ,pp. :
Emerging Immunotargets in Metastatic Renal Cell Carcinoma
Current Drug Targets, Vol. 17, Iss. 7, 2016-06 ,pp. :
Emerging drugs for renal failure
By Chatterjee Prabal K Thiemermann Christoph
Expert Opinion on Emerging Drugs, Vol. 8, Iss. 2, 2003-11 ,pp. :